메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Xinhua Silk Road: Chinese biz leaders hold talks to explore cultural inheritance, innovation

BEIJING, Oct. 31, 2025 -- On Tuesday, an in-depth talk between board chairmen of Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Pien Tze Huang) and Kweichow Moutai Group highlighted joint effort to promote inheritance and innovation of traditional Chinese culture. After discussing related topics such as inheritance of time-honored Chinese brands, Lin Zhihui, board chairman of Pien Tze Huang and Chen Hua, chairman of Kweichow Moutai Group agreed to give full display to the two businesses' demonstration role in this regard. The two Chinese enterprises, whose brands are both fa
- 김갑성 기자
- 2025-10-31 16:15
Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by "Championing the Missions that Matter™"

TAMPA, Fla., Oct. 31, 2025 -- Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscores the company's commitment to delivering unparalleled customer service and its focus on "championing the missions that matter." The new approach reflects Catalent's dedication to helping its pharmaceutical, biotech and consumer health customers bring their life-enhancing and life-changing solutions to those who need them most. "At Catalent, we believe that every medicine, t
- 김갑성 기자
- 2025-10-31 08:30
카탈렌트, 중대한 전환기에 새 브랜드 공개..."Championing the Missions that Matter™" 슬로건으로 고객 서비스 강화

탬파, 플로리다 2025년 10월 31일 -- 글로벌 위탁개발·제조 전문기업 카탈렌트(Catalent)가 오늘 새 브랜드를 공개하며 고객 서비스 차별화와 "의미 있는 사명을 실현하는 데 앞장서다"(championing the missions that matter)는 전략 기조를 공식화했다. 이번 브랜드는 제약·생명공학·소비자 건강 분야에서 고객의 혁신을 지원해 사람들의 삶을 개선하고 변화시키는 솔루션을 가장 필요한 이들에게 제공한다는 철학을 담고 있다. 알레산드로 마셀리(Alessandro Maselli) 대표이사 겸 CEO는 "카탈렌트가 개발·제조·공급하는 모든 제품에는 환자를 최우선으로 하는 철학이 담겨 있다"며 "이번 새 브랜드와 업무 간소화는 카탈렌트의 오늘을 보여주는 동시에, 고객과 함께 목표를 달성하며 세계 보건에 미치는 긍정적 영향을 상징적으로 표현한 것"이라고 말했다. 카탈렌트의 새 브랜드는 2024년 12월 노보 홀딩스(Novo Holdings) 산하 비공개 기업으로 전환한 후 꾸준히 모
- 김갑성 기자
- 2025-10-31 08:30
Singapore Court Confirms GNC's Rights to Assume Former GNC Store Leases from LAC, Setting the Stage for Continued Growth in Singapore

Ruling reduces market confusion and reinforces GNC's science‑backed leadership; company accelerates partnership with Watsons to deliver best‑in‑class wellness solutions for consumers PITTSBURGH, Oct. 31, 2025 -- GNC, the global leader in science‑backed health and wellness, welcomed the Singapore International Commercial Court's ("SICC") decision to uphold an arbitration award requiring ONI Global Pte. Ltd. and LAC Global (Singapore) Pte. Ltd. (collectively, "ONI/LAC Global") to assign to GNC store leases previously operated by ONI/LAC Global as GNC franchise
- 김갑성 기자
- 2025-10-31 07:00
IMG Wins Two 2025 Travel Weekly Magellan Awards

INDIANAPOLIS, Oct. 30, 2025 -- IMG (International Medical Group) has been recognized with two Travel Weekly Magellan Awards for excellence in travel insurance. IMG earned Gold in the Travel Insurance Product category for its renowned iTravelInsured Choice plan and was awarded Silver in the Travel Insurance Customer Service category for its commitment to serving travelers. iTravelInsured Choice was launched in October of 2024 and quickly became IMG's most popular travel protection plan. Designed specifically for cost-conscious travelers spending $10,000 or less per person on the
- 황정호 기자
- 2025-10-30 21:00
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries

[ 메디채널 김갑성 기자 ] NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines' strong clinical and commercialization expertise in Greater China and other Asian markets NovaBridge also named Mr. Ian Woo, President and Chief Financial Officer of Everest Medicines, to its Board of Directors, bringing substantial expertise in international biopharma finance, operations and management VIS-101 is a novel bifunctional biologic targeting VEGF-A/ANG2, with potenti
- 김갑성 기자
- 2025-10-30 16:15
U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)

The U.S. FDA approved STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable with the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications, effective as of October 29, 2025 The interchangeability (IC) designations of STOBOCLO and OSENVELT were granted based not only on the comparative clinical data – including pharmacokinetics, efficacy, safety and an immunogenicity study in postmenopausal women with osteoporosis[1] - but also on analytical data demonstrating similarity of STOBOCLO and OSENV
- 김갑성 기자
- 2025-10-30 15:28
United Imaging Healthcare Q3 2025 Results: In The First Three Quarters Of 2025, Overseas Revenue Up 42% YoY

SHANGHAI, Oct. 30, 2025 -- United Imaging Healthcare (SSE: 688271), a global leader in advanced medical imaging and radiotherapy equipment, has released its financial results for the first three quarters of 2025, showcasing robust financial performance. During this period, the company's revenue and net profit attributable to ordinary shareholders after deducting non-recurring profit, reached CNY 8.86 billion and 1.05 billion, representing a year-over-year increase of 27.39% and 126.94%, respectively. In Q3 2025, the company achieved revenue of CNY 2.84 billion, up 75.41% year on year,
- 김갑성 기자
- 2025-10-30 13:58
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

[ 메디채널 김갑성 기자 ] Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries. Under the assigned exclusive license, Everest Medicines will make an upfront payment of US$7 million (equivalent to approximately RMB49.7 million) and reimburse up to RMB24.0 million for prior expenses; and pay up to US$89.0 million (equivalent to approximately RMB632.0 million) in potential milestones; plus tied royalties on net sales. VIS-101 is a novel bifunctional biologic targeting VEGF-A a
- 김갑성 기자
- 2025-10-30 11:05
LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities

Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market. The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported by joint marketing based on deep ADC expertise. SEOUL, South Korea, Oct. 30, 2025 -- LOTTE BIOLOGICS (CEO James Park) and SK pharmteco (CEO Joerg Ahlgrimm) announced that they have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the g
- 김갑성 기자
- 2025-10-30 09:15

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-11-03_MON

2025-11-02_SUN

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 03일 07시 00분